GLP-1 coverage in Delaware
Medicaid does cover GLP-1s for obesity here. What that means, the indications that are still mandatory, and what it costs if you pay cash.
Updated 2026-09-18
Medicaid coverage of GLP-1s for obesity is optional for states under a long-standing statutory exception. Delaware has exercised that discretion in a specific way.
Delaware Medicaid covers GLP-1s for obesity treatment.
Delaware is among the states KFF lists as covering GLP-1s for obesity treatment as of the April 2026 reporting. Everything below is sourced — we are not going to tell you what a Delaware clinic charges, because every provider we track is 50-state telehealth and prices the same wherever you live. What actually differs by state is coverage, and that is what this page is about.
Why Delaware is different
Delaware is a small programme maintaining coverage while its larger Northeast neighbours cut it — Pennsylvania eliminated coverage, and Massachusetts and Rhode Island have proposals to. Delaware is classified by CDC in the South, and is among the states with adult obesity prevalence at 35% or higher.
Medicaid and GLP-1s in Delaware
Coverage for obesity is optional for states — the national picture is on our coverage index. Here is where Delaware sits.
| Delaware | |
|---|---|
| Status | Medicaid does cover GLP-1s for obesity here |
| Region | South — regional adult obesity prevalence 34.5% |
| Board of pharmacy | Delaware Board of Pharmacy |
If you are on Medicaid in Delaware
What to do in Delaware: Confirm prior-authorisation criteria, and if you are near the Pennsylvania border do not assume regional summaries apply — the two states are now in opposite positions.
Coverage for type 2 diabetes, cardiovascular disease and sleep apnea is mandatory everywhere, so a refusal framed around weight loss is not the end of it — and on Medicare, the $50 programme starts 1 July 2026 regardless of which state you are in.
Read next
- Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
- Who names their pharmacy
The hardest fact to get out of this market, and the one the FDA’s enforcement actually turns on. Here is who publishes it.
- Providers that work your insurance
Prior authorisations, appeals and coverage checks. For anyone whose plan might say yes, this is worth more than any discount.
- Trimi tirzepatide review
Lowest flat price with named pharmacies. What is actually dispensed, how the prescription works, and what the price really is — $125 a month.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure